ESKEF yields 0.25% · JNJ yields 2.13%● Live data
📍 ESKEF pulled ahead of the other in Year 1
Combined, ESKEF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESKEF + JNJ for your $10,000?
Esker SA provides SaaS-based document process automation solutions in France and internationally. The company offers procure-to-pay solutions, which includes supplier and contract management, procurement, AP automation, expense management, and payment and supply chain financing; and order-to-cash solutions, such as order and credit management, invoice delivery, payment, and collections management, as well as cash app and deductions. It also provides document delivery solutions, including cloud fax and mail, e-invoicing, and esker EDI services. In addition, the company offers document automation technologies, including Esker on Demand, a cloud-based document process and information exchange service that enables companies to automate business documents; and VSI-Fax, which provides faxing from enterprise applications along with email-integrated desktop faxing. Further, it provides host access products, which is a software enabling a group of PCs to communicate with a host system, and share peripherals, or access the associated databases; and business process outsourcing tool for incoming non-EDI orders or invoices. The company serves the life sciences, building material, food, electronics, and chemical industries. Esker SA was incorporated in 1985 and is headquartered in Lyon, France.
Full ESKEF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.